Home > Newsletters > FDAnews Drug Daily Bulletin > Analysts See More FDA Concerns With Constipation Drugs Post-CRL
FDAnews Drug Daily Bulletin
Aug. 8, 2012 | Vol. 9 No. 155
Analysts See More FDA Concerns With Constipation Drugs Post-CRL
The FDA’s recent complete response letter (CRL) on Salix’s sNDA for opioid-induced constipation (OIC) drug Relistor likely cites safety concerns and signals increased scrutiny for all makers of these drugs, analysts say. The agency may be cautious about a cardiovascular class-effect in mu-receptor antagonist candidates such as Relistor (methylnaltrexone bromide), Cantor Fitzgerald analyst Irina Rivkind writes.
Washington Drug Letter
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.